Johnson & Johnson (NYSE:JNJ) Stock Holdings Lowered by Traynor Capital Management Inc.

Traynor Capital Management Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 18.5% during the 4th quarter, HoldingsChannel reports. The firm owned 3,619 shares of the company’s stock after selling 823 shares during the quarter. Traynor Capital Management Inc.’s holdings in Johnson & Johnson were worth $523,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Dark Forest Capital Management LP bought a new stake in Johnson & Johnson during the 2nd quarter valued at $223,000. Peloton Wealth Strategists increased its holdings in shares of Johnson & Johnson by 3.1% during the second quarter. Peloton Wealth Strategists now owns 16,749 shares of the company’s stock valued at $2,448,000 after purchasing an additional 496 shares during the period. Texas Capital Bancshares Inc TX raised its stake in shares of Johnson & Johnson by 26.3% during the second quarter. Texas Capital Bancshares Inc TX now owns 5,268 shares of the company’s stock valued at $770,000 after purchasing an additional 1,096 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc lifted its holdings in Johnson & Johnson by 25.6% in the second quarter. Texas Capital Bank Wealth Management Services Inc now owns 4,997 shares of the company’s stock worth $730,000 after purchasing an additional 1,019 shares during the period. Finally, Bontempo Ohly Capital Mgmt LLC increased its stake in Johnson & Johnson by 0.8% during the 2nd quarter. Bontempo Ohly Capital Mgmt LLC now owns 14,650 shares of the company’s stock valued at $2,141,000 after buying an additional 115 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. Raymond James decreased their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday. Guggenheim lifted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Bank of America cut their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $170.06.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $146.76 on Friday. The company has a market capitalization of $353.34 billion, a price-to-earnings ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock’s fifty day simple moving average is $147.85 and its 200-day simple moving average is $155.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.